Myers Wendy A, Najarian David, Gottlieb Alice B
Department of Medicine, Division of Clinical Pharmacology, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08903, USA.
J Dermatolog Treat. 2006;17(6):353-4. doi: 10.1080/09546630600967406.
Efalizumab is a humanized anti-CD11a monoclonal IgG(1) antibody approved for the treatment of moderate-to-severe plaque psoriasis. This case report describes two cases of new-onset debilitating psoriatic arthritis in patients with plaque psoriasis on long-standing efalizumab therapy, despite the fact that their skin disease was in remission. Although during the clinical trials, involving over 2,700 study subjects, arthralgia was seen only at a rate of 1-2% higher than in those subjects receiving placebo, the cases presented here are interesting in that it appears that efalizumab treatment 'uncoupled' the psoriatic arthritic component from the cutaneous disease. It can be speculated that a possible mechanism for efalizumab-induced psoriatic arthritis is related to the blockade of regulatory T cells from joint tissue.
依法利珠单抗是一种人源化抗CD11a单克隆IgG(1)抗体，被批准用于治疗中重度斑块状银屑病。本病例报告描述了两例长期接受依法利珠单抗治疗的斑块状银屑病患者出现新发致残性银屑病关节炎的病例，尽管他们的皮肤病处于缓解期。虽然在涉及超过2700名研究对象的临床试验中，关节痛的发生率仅比接受安慰剂的受试者高1-2%，但此处呈现的病例很有意思，因为依法利珠单抗治疗似乎使银屑病关节炎成分与皮肤病“脱钩”。可以推测，依法利珠单抗诱发银屑病关节炎的一种可能机制与关节组织中调节性T细胞的阻断有关。
